VJHemOnc – The video journal of hematological oncology

The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

The European Commission approves belantamab mafodotin for the treatment of patients with RRMM

On August 26, 2020, the European Commission granted a conditional marketing authorization to belantamab mafodotin for the treatment of adult patients with RRMM who have previously received at least four therapies.

VJHemOnc – The video journal of hematological oncology

The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

Dr. Davies on Personalizing Treatment in Relapsed/Refractory Myeloma

Faith E. Davies, MD, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Approved in Europe for Relapsed/Refractory Multiple Myeloma

The European Commission has approved belantamab mafodotin-blmf for the treatment of adult patients with multiple myeloma who have received at least 4 previous therapies, whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody, and who have progressed on their last therapy.

Personalized Approach Is Needed for Transplant-Ineligible Multiple Myeloma

Smith Giri, MD, MHS, discusses the options available for transplant-ineligible patients with myeloma, the factors to consider to personalize treatment, and future directions in the field.

Clinical Data Establish Role of Triplet Therapies in Relapsed Multiple Myeloma

Shagun D. Arora, MD, discusses findings from the phase 3 CANDOR, ICARIA-MM, and IKEMA studies which solidified the role of triplet regimens versus doublets in the relapsed/refractory multiple myeloma treatment landscape.

VJHemOnc – The video journal of hematological oncology

The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

Initial Results From the Phase III BOSTON Study for Multiple Myeloma

Selinexor, the orally bioavailable first-in-class selective inhibitor of nuclear export (SINE) was initially approved by the FDA in July 2019 in combination with dexamethasone for previously treated patients with relapsed or refractory multiple myeloma. Currently, in the phase III BOSTON trial (NCT03110562), which is a two-arm, randomized, active comparator-controlled, open-label, multicenter…

The impact of sarcopenia in patients with multiple myeloma undergoing auto-HCT

Alexis Williams and colleagues published in Bone Marrow Transplantation the results of a single-center, retrospective analysis that evaluated the impact of sarcopenia in patients with MM undergoing autologous hematopoietic cell transplantation